Michael Martin Breen

CIK: 0001863633

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GTBP

GT Biopharma, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

GTBP
GT Biopharma, Inc.
Sep 4, 2025
Award(A)
Option to purchase Common Stock
Direct
100K shares-
GTBP
GT Biopharma, Inc.
Sep 4, 2025
Award(A)
Option to purchase Common Stock
Direct
100K shares-
GTBP
GT Biopharma, Inc.
Sep 4, 2025
Award(A)
Option to purchase Common Stock
Direct
100K shares-

		Type	Shares	Price		Ownership
Sep 4, 2025	GTBP GT Biopharma, Inc.	Award(A) Option to purchase Common Stock	100,000	-	-	Direct
Sep 4, 2025	GTBP GT Biopharma, Inc.	Award(A) Option to purchase Common Stock	100,000	-	-	Direct
Sep 4, 2025	GTBP GT Biopharma, Inc.	Award(A) Option to purchase Common Stock	100,000	-	-	Direct

1-3 of 3 transactions

About Breen Michael Martin

Breen Michael Martin (SEC CIK 0001863633) files insider reports with the SEC as CEO and Director of GT Biopharma, Inc. (GTBP).

Signal8 holds 1 ownership filing by Breen Michael Martin, a Form 4, filed on Sep 8, 2025. Those filings report 3 transactions, the latest on Sep 4, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Breen Michael Martin's filings is in SAN FRANCISCO, CA.

Recent filings by Breen Michael Martin

Sep 4, 2025: Grants or awards of GTBP derivative securities (3 lines, Form 4, code A).

Other insiders filing for GT Biopharma, Inc. (GTBP)

Mun-Gavin David C., Director
URBAN ALAN LOUIS, Chief Financial Officer
CASAMENTO CHARLES J, Director
Kramer Hilary, Director
Ritter Andrew J, Director

How to read Form 4 transaction codes